Clinical trials: Neoplasms, Pharyngeal
Melanoma, Non-small Cell Lung Cancer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT03329950
- Testing
- CDX-1140, CDX-301, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma
Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin
This phase I trial investigates the side effects and best dose of peposertib when given together with radiation therapy in treating patients with head and neck cancer that has spread to other places in the body (advanced) who…
- Conditions
- Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT04533750
- Testing
- Intensity-Modulated Radiation Therapy, Peposertib
- Where
- 27 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
By doing this study, the research team would like to learn if using a blood test that measures the amount of tumor DNA in blood can help guide how to use chemotherapy combined with immunotherapy for individuals with head and neck…
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Neoplasms, Head Cancer
- Trial name
- NCT05420948
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago
Nasopharyngeal Carcinoma
A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy
The goal of this clinical trial is to compare the efficacy and safety of curative radiotherapy with or without induction chemotherapy in patients with T3N1M0 nasopharyngeal carcinoma.
- Trial name
- NCT05622474
- Testing
- Induction chemotherapy plus Concurrent chemotherapy, Concurrent chemotherapy, IMRT
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Sun Yat-sen University
Bladder Cancer, Cervical Cancer
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
RATIONALE: Stop-smoking plans, including counseling and nicotine replacement therapy, may help smokers quit smoking. It is not yet known whether counseling and the nicotine lozenge is more effective than counseling and the…
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00365508
- Testing
- nicotine lozenge, nicotine patch
- Where
- 10 sites in United States
- Volunteers
- 642 people
- Sponsor
- Fox Chase Cancer Center
Nasopharyngeal Carcinoma (NPC)
Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma
Immunotherapy combined with chemoradiotherapy has become standard care for locally advanced nasopharyngeal carcinoma, yet radiotherapy-induced lymphopenia may impair the efficacy of concurrent PD-1 blockade.
- Trial name
- NCT07706985
- Testing
- Toripalimab combined with Nimotuzumab, Nimotuzumab
- Where
- China
- Volunteers
- 566 people
- Sponsor
- Sun Yat-sen University
Hypopharyngeal Neoplasm Malignant Primary
Toripalimab Plus TPF Chemotherapy and Radiotherapy for LA-HPSCC
TPF is the standard regime of inductive chemotherapy for squamous carcinoma of head and neck. If the primary tumor shrinks obviously (complete remission or >75% partial remission )after inductive chemotherapy, CCRT is suggested…
- Trial name
- NCT04624308
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Sun Yan
Nasopharyngeal Carcinoma
Prospective Nasopharyngeal Carcinoma Screening Using Plasma Epstein-Barr Virus DNA Analysis
The purpose of this study is to determine if the screening of nasopharyngeal carcinoma using plasma Epstein-Barr virus DNA analysis would result in the detecting NPC cases at earlier stages and improve survival.
- Trial name
- NCT02063399
- Where
- Hong Kong
- Volunteers
- 20,302 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Hypopharyngeal Cancer
New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma
To develope stratification treatment for the patients who have locally advanced hypopharyngeal carcinoma. Experimental group patients were treated individually according to the response status after induction chemotherapy…
- Trial name
- NCT03558035
- Testing
- Induction CT+ CRT group, Concurrent CRT group
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Chinese Academy of Medical Sciences
Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma Screening in Zhongshan City
The primary objective is to determine the early diagnosis rate and mortality rate of the Nasopharyngeal Carcinoma (NPC) in the study population. The secondary objective is to determine the incidence of NPC in the study population.
- Trial name
- NCT02501993
- Where
- China
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Zhongshan People's Hospital, Guangdong, China
Oral Cancer, Oropharyngeal Cancer
Speech-based AI-driven Diagnostics and Rehabilitation for Oral and Oropharyngeal Cancer.
Participants diagnosed with oral cancer, oropharyngeal cancer, or oral potentially malignant lesions, as well as healthy controls, had their speech audio recordings collected for the development and validation of AI-driven models…
- Trial name
- speech omics (NCT07347899)
- Where
- China
- Volunteers
- 501 people, healthy volunteers welcome
- Sponsor
- Yudong Xiao
Oropharynx Cancer
Bitter Taste Receptors in Oropharynx Cancer
The aim of this work is to investigate the expression of the bitter taste receptors in p16-positive and negative oropharyngeal carcinomas (in comparison to healthy, local tissue).
- Trial name
- NCT05211427
- Testing
- Biopsy
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Thomas Hummel
Head and Neck Squamous Cell Carcinoma, Cancer
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
The purpose of this study is to compare any good or bad effects of using pembrolizumab (an experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and radiation therapy (RT) in the treatment of…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Cancer, Cancer of Head and Neck, Cancer, Advanced
- Trial name
- NCT03383094
- Testing
- Pembrolizumab, Radiation therapy, Cisplatin
- Where
- 6 sites in United States
- Volunteers
- 126 people
- Sponsor
- Loren Mell, MD
Nasopharyngeal Carcinoma, Metastasis
Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma
The treatment of distant metastasis is a key challenge for nasopharyngeal carcinoma because of poor outcomes, among which, chemotherapy is the cornerstone.
- Conditions
- Nasopharyngeal Carcinoma, Metastasis, Chemotherapy, Survival
- Trial name
- NCT04472403
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Sun Yat-sen University
Locally Recurrent Cancer, Metastatic Nasopharyngeal Cancer
Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC
This is a single center, randomized, phase Ib/II open-label study of pembrolizumab (pembro or MK-3475) with or without bevacizumab in patients with recurrent non-curable or metastatic nasopharyngeal carcinoma (NPC).
- Trial name
- 2018/00947 (NCT03813394)
- Testing
- pembrolizumab, bevacizumab
- Where
- Singapore
- Volunteers
- 48 people
- Sponsor
- National University Hospital, Singapore
Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma
Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma
Oropharyngeal squamous cell carcinoma (OPSCC) is now the most frequently diagnosed head and neck cancer in Denmark which is mainly due to the increase of Human Papillomavirus (HPV).
- Conditions
- Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Carcinoma
- Trial name
- QoLATI (NCT04124198)
- Testing
- Intensity-Modulated Radiation Therapy (IMRT), Cisplatin, Nimorazole.
- Where
- 3 sites in Denmark
- Volunteers
- 138 people
- Sponsor
- Christian von Buchwald
Adult Solid Tumor
Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
This is a Phase 1/2, first-in-human, open label, multicenter study to assess safety and tolerability, antitumor activity, and immunogenic and pharmacodynamic effects of SQZ-eAPC-HPV as monotherapy and in combination with…
- Trial name
- NCT05357898
- Testing
- SQZ-eAPC-HPV, Pembrolizumab
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- SQZ Biotechnologies
Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative
- Trial name
- DUET-3 (NCT03752398)
- Testing
- XmAb®23104, Yervoy® (ipilimumab)
- Where
- 18 sites in United States
- Volunteers
- 198 people
- Sponsor
- Xencor, Inc.
Metastatic Nasopharyngeal Cancer
High-activity Natural Killer Immunotherapy for Small Metastases of Nasopharyngeal Cancer
The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of nasopharyngeal cancer.
- Trial name
- NCT03007836
- Testing
- High-activity natural killer
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Trial name
- NCT05136196
- Testing
- Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate
- Where
- 232 sites in United States
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.